

EID Updates:

Emerging and Reemerging Infectious Diseases, Region of the Americas

Vol. 5, No. 10 (27 March 2008) <u>Main Updates index</u>

Final Statement by PAHO/WHO on Investigation of Serious Adverse Events in Peru following Receipt of Yellow Fever Vaccine Produced by Bio-Manguinhos, Brazil

This <u>PAHO/WHO statement</u> provides results of the investigation of serious adverse events that occurred in October 2007 in Peru following administration of the yellow fever vaccine (substrain 17DD) manufactured by Bio-Manguinhos, Brazil. It contains the conclusions of the expert group as well as their recommendations.

A previous PAHO/WHO statement on the reported events was issued on 2 November 2007 and recommended temporary suspension of specific lots of the vaccine.

Source: PAHO/WHO Immunization Unit, Family and Community Health Area.